Sofosbuvir and Velpatasvir Monograph for Professionals.
Sofosbuvir-Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor and velapatasvir, an NS5A replication complex inhibitor. Sofosbuvir is currently approved in the United States for the treatment of genotype 1, 2, 3 and 4 HCV infection with different regimens and durations dependent on the HCV genotype. Velpatasvir (formerly GS-5816) is a.A list of drugs that interact with Velpatasvir. Velpatasvir is predicted to increase the exposure to simvastatin. Manufacturer advises monitor side effects and adjust dose.World's Largest Inventory of Certified Reference Standards. Contact Us Right Here. Thanks for showing an interest. We need some basic information from you to serve you better.
Sofosbuvir and velpatasvir are both DAAs with activity against HCV. 1 No in vitro evidence of antagonistic anti-HCV effects between the drugs in HCV replicon studies. 1. Sofosbuvir is a prodrug that undergoes metabolic activation in the liver to a pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by NS5B polymerase; 1 acts as RNA chain.Velpatasvir is a NS5A inhibitor, preventing HCV viral RNA replication and virion assembly, and is administered in combination with sofosbuvir, a HCV NS5B polymerase inhibitor with established pharmacological properties, already included on the WHO Essential Medicines.
A complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes.
